IP Library › Granted Patent US 7,867,483
Granted Patent B2
US 7,867,483 · App. 12/253,094 · Granted Jan 11, 2011

Use of MVA to treat prostate cancer

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,867,483
App. No.
12/253,094
Granted
Jan 11, 2011
Kind
B2
Abstract

The invention relates to compositions, kits, and methods for cancer prophylaxis and therapy using recombinant MVA viruses encoding tumor-associated antigens, such as PSA and PAP. The recombinant MVA viruses can induce B- and T-cell responses. The recombinant MVA viruses can be administered prior to, at the same time as, or after a taxane.

Claims (13)

1. A method for treating a human prostate cancer patient comprising administering to the human patient a recombinant modified vaccinia virus Ankara (MVA) encoding a polypeptide comprising a human prostate-specific antigen (PSA) antigen and a polypeptide comprising a human prostatic acid phosphatase (PAP) antigen.

2. The method of claim 1 , wherein the MVA is modified vaccinia virus Ankara-Bavarian Nordic (MVA-BN).

3. The method of claim 1 , wherein the MVA virus comprises the nucleotide sequences of SEQ ID NO:1 and SEQ ID NO:2.

4. The method of claim 1 , wherein a nucleic acid molecule encoding the PSA antigen and the PAP antigen are inserted in the MVA intergenic region 014L/015L.

5. The method of claim 1 , wherein the cancer is prostate cancer in the patient is of metastasis.

6. The method of claim 1 , wherein the recombinant MVA is administered prior to a tumoricidal dose of a taxane.

7. The method of claim 1 , wherein the recombinant MVA is administered at the same time as a tumoricidal dose of a taxane.

8. The method of claim 1 , wherein the recombinant MVA is administered after a tumoricidal dose of a taxane.

9. The method of claim 6 , wherein the taxane is docetaxel or paclitaxel.

10. The method of claim 8 , wherein the taxane is docetaxel or paclitaxel.

11. The method of claim 1 comprising administering to the patient a priming dose of the recombinant MVA and administering one or more boosting doses of the recombinant MVA.

12. The method of claim 11 , wherein a priming dose of 1×10 8 TCID 50 and two boosting doses of 2×10 8 and 4×10 8 TCID 50 are administered to the patient.

13. The method of claim 12 , wherein the boosting doses are given at four and eight weeks after the priming dose.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 27, 2016
From: BAVARIAN NORDIC INC.
To: BAVARIAN NORDIC A/S
Reel/Frame 037601/0048 →
CHANGE OF NAME Recorded Aug 7, 2013
From: BN IMMUNOTHERAPEUTICS, INC.
To: BAVARIAN NORDIC, INC.
Reel/Frame 030965/0065 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 3, 2008
From: DELCAYRE, ALAIN; LAUS, REINER; MANDL, STEFANIE; ROUNTREE, RYAN BLAIR; LEGRAND, FATEMA
To: BN IMMUNOTHERAPEUTICS INC.
Reel/Frame 021777/0671 →